(Q79657104)
Statements
A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response (English)
S M H Alibhai
J M Brandwein
L Yang
A C Schuh
V Gupta
R A Wells
W Xu
25 January 2007